(Q39415339)

11 September 2017

1 reference

title

Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis (English)

1 reference

11 September 2017

1 reference

1 reference

Yuji Sakuma

1

1 reference

11 September 2017

publication date

5 July 2017

1 reference

11 September 2017

published in

Pathology International

1 reference

11 September 2017

volume

67

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

379-388

1 reference

Moving treatment-free remission into mainstream clinical practice in CML.

11 September 2017

cites work

1 reference

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

21 January 2018

1 reference

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

21 January 2018

1 reference

NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression

21 January 2018

1 reference

Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis

21 January 2018

1 reference

Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix

21 January 2018

1 reference

Idiopathic pulmonary fibrosis

21 January 2018

1 reference

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier

21 January 2018

1 reference

Advances in target therapy for lung cancer

21 January 2018

1 reference

Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations

21 January 2018

1 reference

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma

21 January 2018

1 reference

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

21 January 2018

1 reference

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

21 January 2018

1 reference

Acquired resistance to TKIs in solid tumours: learning from lung cancer

21 January 2018

1 reference

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

21 January 2018

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

21 January 2018

1 reference

Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype

21 January 2018

1 reference

The epigenetics of epithelial-mesenchymal plasticity in cancer

21 January 2018

1 reference

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

21 January 2018

1 reference

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

21 January 2018

1 reference

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

21 January 2018

1 reference

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1

21 January 2018

1 reference

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

21 January 2018

1 reference

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

21 January 2018

1 reference

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

21 January 2018

1 reference

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.

21 January 2018

1 reference

Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side

21 January 2018

1 reference

Cellular interactions in the pathogenesis of interstitial lung diseases

21 January 2018

1 reference

Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis

21 January 2018

1 reference

Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition

21 January 2018

1 reference

Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

Disproportionate representation ofKRAS gene mutation in atypical adenomatous hyperplasia, but even distribution ofEGFR gene mutation from preinvasive to invasive adenocarcinomas

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/PIN.12553

1 reference

11 September 2017

1 reference